Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo de revisión (ReviewArticle)

Subclinical atherosclerosis and brain health in midlife: Rationale and design of the PESA-Brain study.

  • Tristão-Pereira, Catarina
  • Fuster, Valentin
  • Lopez-Jimenez, Alejandro
  • Fernández-Pena, Alberto
  • Semerano, Aurora
  • Fernandez-Nueda, Irene
  • Garcia-Lunar, Ines
  • Ayuso, Carmen
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
  • Tristão-Pereira, Catarina
  • Fuster, Valentin
  • Lopez-Jimenez, Alejandro
  • Fernández-Pena, Alberto
  • Semerano, Aurora
  • Fernandez-Nueda, Irene
  • Garcia-Lunar, Ines
  • Ayuso, Carmen
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Gispert, Juan Domingo
  • Cortes-Canteli, Marta
Cognitive decline and dementia have been reportedly linked to atherosclerosis, the main cause of cardiovascular disease. Cohort studies identifying early brain alterations associated with subclinical atherosclerosis are warranted to understand the potential of prevention strategies before cerebral damage becomes symptomatic and irreversible. The Progression of Early Subclinical Atherosclerosis (PESA) study is a longitudinal observational cohort study that recruited 4,184 asymptomatic middle-aged individuals (40-54 years) in 2010 in Madrid (Spain) to thoroughly characterize subclinical atherosclerosis development over time. In this framework, the PESA-Brain study has been designed to identify early structural, functional and vascular brain changes associated with midlife atherosclerosis and cardiovascular risk factors. The PESA-Brain study targets 1,000 participants at the 10-year follow-up PESA visit and consists of thorough neuropsychological testing, advanced multimodal neuroimaging, and quantification of blood-based neuropathological biomarkers. We hypothesize that, in middle-age, the presence of cardiovascular risk factors and a high burden of subclinical atherosclerosis will be associated with structural, functional and vascular brain alterations, greater amyloid burden and subtle cognitive impairment. We further hypothesize that the link between subclinical atherosclerosis and poor brain health in midlife will be mediated by cerebrovascular pathology and intracranial atherosclerosis. Enrollment dates: The PESA-Brain study started in October 2020 and is estimated to be completed by December 2024. Conclusion: This study is in a unique position to unveil novel relationships between cardiovascular and brain alterations in the health-to-disease transition, which may have important implications for interventional and therapeutic approaches.
Repisalud
Publicación Artículo científico (JournalArticle)

Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions

  • Kostaki, Evangelia-Georgia
  • Flampouris, Andreas
  • Karamitros, Timokratis
  • Chueca, Natalia
  • Alvarez, Marta
  • Casas, Paz
  • Alejos, Belén
  • Hatzakis, Angelos
  • García, Federico
  • Paraskevis, Dimitrios
  • CoRIS Cohort
  • Thomson, Michael M
  • Delgado, Elena
  • Benito, Sonia
  • Montero, Vanessa
Background and Aim: The circulating recombinant form 02_AG (CRF02_AG) is the predominant clade among the human immunodeficiency virus type-1 (HIV-1) non-Bs with a prevalence of 5.97% (95% Confidence Interval-CI: 5.41-6.57%) across Spain. Our aim was to estimate the levels of regional clustering for CRF02_AG and the spatiotemporal characteristics of the largest CRF02_AG subepidemic in Spain. Methods: We studied 396 CRF02_AG sequences obtained from HIV-1 diagnosed patients during 2000-2014 from 10 autonomous communities of Spain. Phylogenetic analysis was performed on the 391 CRF02_AG sequences along with all globally sampled CRF02_AG sequences (N = 3,302) as references. Phylodynamic and phylogeographic analysis was performed to the largest CRF02_AG monophyletic cluster by a Bayesian method in BEAST v1.8.0 and by reconstructing ancestral states using the criterion of parsimony in Mesquite v3.4, respectively. Results: The HIV-1 CRF02_AG prevalence differed across Spanish autonomous communities we sampled from (p < 0.001). Phylogenetic analysis revealed that 52.7% of the CRF02_AG sequences formed 56 monophyletic clusters, with a range of 279 sequences. The CRF02_AG regional dispersal differed across Spain (p = 0.003), as suggested by monophyletic clustering. For the largest monophyletic cluster (subepidemic) (N = 79), 49.4% of the clustered sequences originated from Madrid, while most sequences (51.9%) had been obtained from men having sex with men (MSM). Molecular clock analysis suggested that the origin (t(MRCA)) of the CRF02_AG subepidemic was in 2002 (median estimate; 95% Highest Posterior Density-HPD interval: 1999-2004). Additionally, we found significant clustering within the CRF02_AG subepidemic according to the ethnic origin. Conclusion: CRF02_AG has been introduced as a result of multiple introductions in Spain, following regional dispersal in several cases. We showed that CRF02_AG transmissions were mostly due to regional dispersal in Spain. The hot-spot for the largest CRF02_AG regional subepidemic in Spain was in Madrid associated with MSM transmission risk group. The existence of subepidemics suggest that several spillovers occurred from Madrid to other areas. CRF02_AG sequences from Hispanics were clustered in a separate subclade suggesting no linkage between the local and Hispanic subepidemics.
Repisalud
Publicación Artículo científico (JournalArticle)

Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals: The PESA Study.

  • Cortes-Canteli, Marta
  • Gispert, Juan Domingo
  • Salvadó, Gemma
  • Toribio-Fernandez, Raquel
  • Tristão-Pereira, Catarina
  • Falcon, Carles
  • Oliva, Belen
  • Mendiguren, Jose M
  • Fernandez-Friera, Leticia
  • Sanz, Javier
  • Garcia-Ruiz, Jose M
  • Fernandez-Ortiz, Antonio
  • Sanchez-Gonzalez, Javier
  • Ibáñez, Borja
  • Molinuevo, José Luis
  • Fuster, Valentin
Atherosclerosis has been linked to cognitive decline in late life; however, the impact of cardiovascular risk factors (CVRFs) and subclinical atherosclerosis on brain metabolism at earlier stages remains unexplored. This study sought to determine the association between brain metabolism, subclinical atherosclerosis, and CVRFs in middle-aged asymptomatic individuals. This study included 547 asymptomatic middle-aged participants (50 ± 4 years, 82% men) from the PESA (Progression of Early Subclinical Atherosclerosis) study with evidence of subclinical atherosclerosis. Participants underwent 18F-fluorodeoxyglucose (FDG)-positron emission tomography. Global brain FDG uptake and voxel-wise analyses were used to evaluate the associations of cerebral metabolism with CVRFs and atherosclerotic plaque burden in carotids and femorals assessed by 3-dimensional vascular ultrasound. Global FDG uptake showed an inverse correlation with 30-year Framingham Risk Score (FRS) (β = -0.15, p < 0.001). This association was mainly driven by the presence of hypertension (d = 0.36, p < 0.001). Carotid plaque burden was inversely associated with global brain FDG uptake (β = -0.16, p < 0.001), even after adjusting for 30-year FRS. Voxel-wise approaches revealed that the brain areas most strongly affected by hypometabolism in association with 30-year FRS, hypertension, and carotid plaque burden were parietotemporal regions (angular, supramarginal, and inferior/middle temporal gyri) and the cingulate gyrus. In asymptomatic middle-aged individuals, cardiovascular risk is associated with brain hypometabolism, with hypertension being the modifiable CVRF showing the strongest association. Subclinical carotid plaque burden is also linked to reduced brain metabolism independently of CVRFs. Cerebral areas showing hypometabolism include those known to be affected in dementia. These data reinforce the need to control CVRFs early in life in order to potentially reduce the brain's midlife vulnerability to future cognitive dysfunction.
Docta Complutense
Publicación Artículo científico (JournalArticle)

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

  • Goikoetxea Usandizaga, Naroa
  • Bravo, Miren
  • Egia Mendikute, Leire
  • Abecia, Leticia
  • Serrano Maciá, Marina
  • Urdinguio, Rocío G.
  • Clos García, Marc
  • Rodríguez Agudo, Rubén
  • Araujo Legido, Raquel
  • López Bermudo, Lucía
  • Delgado, Teresa C.
  • Lachiondo Ortega, Sofía
  • González Recio, Irene
  • Gil Pitarch, Clàudia
  • Peña Cearra, Ainize
  • Simón, Jorge
  • Benede Ubieto, Raquel
  • Ariño, Silvia
  • Herranz, Jose M.
  • Azkargorta, Mikel
  • Salazar Bermeo, Julio
  • Martí, Nuria
  • Varela Rey, Marta
  • Falcón Pérez, Juan M.
  • Lorenzo, Óscar
  • Nogueiras, Rubén
  • Elortza, Félix
  • Nevzorova, Yulia
  • Cubero Palero, Francisco Javier
  • Saura, Domingo
  • Martínez Cruz, Luis Alfonso
  • Sabio, Guadalupe
  • Palazón, Asís
  • Sancho Bru, Pau
  • Elguezabal, Natalia
  • Fraga, Mario F.
  • Ávila, Matías A.
  • Bataller, Ramón
  • Marín, José J.G.
  • Martín, Franz
  • Martínez Chantar, María Luz
Background and Aims: Alcohol-associated liver disease (ALD) accounts for 70% of liver-related deaths in Europe, with no effective approved therapies. Although mitochondrial dysfunction is one of the earliest manifestations of alcohol-induced injury, restoring mitochondrial activity remains a problematic strategy due to oxidative stress. Here, we identify methylation-controlled J protein (MCJ) as a mediator for ALD progression and hypothesize that targeting MCJ may help in recovering mitochondrial fitness without collateral oxidative damage. Approach and Results: C57BL/6 mice [wild-type (Wt)] Mcj knockout and Mcj liver-specific silencing (MCJ-LSS) underwent the NIAAA dietary protocol (Lieber-DeCarli diet containing 5% (vol/vol) ethanol for 10 days, plus a single binge ethanol feeding at day 11). To evaluate the impact of a restored mitochondrial activity in ALD, the liver, gut, and pancreas were characterized, focusing on lipid metabolism, glucose homeostasis, intestinal permeability, and microbiota composition. MCJ, a protein acting as an endogenous negative regulator of mitochondrial respiration, is downregulated in the early stages of ALD and increases with the severity of the disease. Whole-body deficiency of MCJ is detrimental during ALD because it exacerbates the systemic effects of alcohol abuse through altered intestinal permeability, increased endotoxemia, and dysregulation of pancreatic function, which overall worsens liver injury. On the other hand, liver-specific Mcj silencing prevents main ALD hallmarks, that is, mitochondrial dysfunction, steatosis, inflammation, and oxidative stress, as it restores the NAD+/NADH ratio and SIRT1 function, hence preventing de novo lipogenesis and improving lipid oxidation. Conclusions: Improving mitochondrial respiration by liver-specific Mcj silencing might become a novel therapeutic approach for treating ALD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia

  • Alonso-Peña, Marta|||0000-0003-0934-2202
  • Espinosa-Escudero, Ricardo
  • Herraez, Elisa
  • Briz, Oscar
  • Cagigal, Maria Luisa
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Ortega-Alonso, Aida|||0000-0002-8999-4093
  • Fernandez-Rodriguez, Conrado
  • Bujanda, Luis|||0000-0002-4353-9968
  • Calvo Sanchez, Marta
  • D'Avola, Delia
  • Londoño, Maria Carlota|||0000-0002-6533-1586
  • Diago, Moises|||0000-0002-8583-2433
  • Fernandez-Checa, Jose C.
  • Garcia-Ruiz, Carmen
  • Andrade, Raúl J.
  • Lammert, Frank
  • Prieto, Jesus
  • Crespo García, Javier|||0000-0001-8248-0172
  • Juamperez, Javier|||0000-0002-8556-6374
  • Díaz-González, Álvaro|||0000-0003-3610-2263
  • Monte, Maria J.|||0000-0003-1844-7428
  • Marin, Jose J. G.|||0000-0003-1186-6849
A variant (p.Arg225Trp) of peroxisomal acyl-CoA oxidase 2 (ACOX2), involved in bile acid (BA) side-chain shortening, has been associated with unexplained persistent hypertransaminasemia and accumulation of C27-BAs, mainly 3α,7α,12α-trihydroxy-5β-cholestanoic acid (THCA). We aimed to investigate the prevalence of ACOX2 deficiency-associated hypertransaminasemia (ADAH), its response to ursodeoxycholic acid (UDCA), elucidate its pathophysiological mechanism and identify other inborn errors that could cause this alteration. Among 33 patients with unexplained hypertransaminasemia from 11 hospitals and 13 of their relatives, seven individuals with abnormally high C27-BA levels (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Outcome of liver cancer patients with SARS-CoV-2 infection, An International, Multicentre, Cohort Study

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Ríos, José|||0000-0002-0716-8784
  • Bouattour, Mohamed|||0000-0002-3919-4135
  • El-Kassas, Mohamed|||0000-0002-3396-6894
  • Leal, Cassia R. G.
  • Mocan, Tudor|||0000-0001-7785-6403
  • Nault, Jean-Charles|||0000-0002-4875-9353
  • Alves, Rogerio C. P.
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • García-Juárez, Ignacio|||0000-0003-2400-1887
  • Pinato, David James|||0000-0002-3529-0103
  • Varela Calvo, Maria|||0000-0003-4288-2593
  • Alqahtani, Saleh|||0000-0003-2017-3526
  • Alvares-da-Silva, Mario R.|||0000-0002-5001-246X
  • Bandi, Juan C.|||0000-0001-9733-1938
  • Rimassa, Lorenza|||0000-0001-9957-3615
  • Lozano, Mar|||0000-0001-7099-0810
  • González Santiago, Jesús M.|||0000-0003-4667-4492
  • Tacke, Frank|||0000-0001-6206-0226
  • Sala, Margarita
  • Anders, María|||0000-0002-2238-5322
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Piñero, Federico
  • França, Alex
  • Guarino, Maria|||0000-0002-0460-4122
  • Elvevi, Alessandra
  • Cabibbo, Giuseppe|||0000-0002-0946-3859
  • Peck-Radosavljevic, Markus|||0000-0002-0597-2728
  • Rojas, Ángela|||0000-0003-0853-4800
  • Vergara, Mercedes|||0000-0002-6971-8657
  • Braconi, Chiara|||0000-0003-4835-1259
  • Pascual, Sonia|||0000-0002-4265-5019
  • Perelló, Christie|||0000-0003-0234-2330
  • Mello, Vivianne
  • Rodríguez Lope, Carlos|||0000-0002-6713-8800
  • Acevedo, Juan|||0000-0003-4507-2422
  • Villani, Rosanna|||0000-0001-9875-019X
  • Hollande, Clemence|||0000-0002-2287-0635
  • Vilgrain, Valérie
  • Tawheed, Ahmed|||0000-0002-9382-8733
  • Ferguson Theodoro, Carmem|||0000-0001-6605-1060
  • Sparchez, Zeno
  • Blaise, Lorraine
  • Viera-Alves, Daniele E.
  • Watson, Robyn
  • Carrilho, Flair J.
  • Moctezuma-Velázquez, Carlos|||0000-0003-2367-2742
  • D'Alessio, Antonio
  • Iavarone, Massimo|||0000-0003-3493-6504
  • Reig, María|||0000-0002-5711-9534
Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p =.0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p =.5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p =.0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection. This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.